Background: Desmoplastic infantile astrocytoma (DIA) and desmoplastic infantile gangliogliomas (DIGs) are rare, massive, cystic and solid tumors of infants usually found in superficial cerebral hemispheres. They manifest prominent desmoplastic stroma, admixed neoplastic astrocytes, primitive-appearing small cells, and additional neoplastic ganglion cells in the case of DIGs. While v-Raf murine sarcoma viral oncogene homolog B (BRAF) mutation is found in up to 50% of pediatric gangliogliomas, two recent studies found that it was rare in DIA/DIGs; we sought to assess BRAF status in DIA/DIGs from our institution.
INTRODUCTION
Desmoplastic infantile astrocytoma (DIA) and desmoplastic infantile ganglioglioma (DIG) are massive, enhancing, cystic and solid, superficially located tumors usually found in the cerebral hemisphere. The majority occur in infants less than 24 months of age, with a median of 6 months. 1 Tumors are slow growing, and World Health OrganizaAbbreviations: BRAF, v-Raf murine sarcoma viral oncogene homolog B; DIA, desmoplastic infantile astrocytoma; DIG, desmoplastic infantile ganglioglioma; GFAP, glial fibrillary acidic protein; IHC, immunohistochemistry; WHO, World Health Organization tion (WHO) grade I, despite their ominous neuroimaging appearance, and thus are usually curable by gross total surgical excision. 1 However, recent literature reviews 2, 3 emphasize that in the subset in which gross total resection is not feasible due to deep location, massive size, and/or bilateral extension, 3 further surgical, radiation therapy, or chemotherapy has been necessary. Thus, identifying mutations for which targeted therapies exist has clinical value in treating a subset of these tumors.
DIA and DIG were originally described as separate tumor entities, 4, 5 were recently further emphasized by Gessi et al., who, by genome-wide DNA copy number analysis, showed that large chromosomal changes were rare in either tumor type, but both shared focal genomic losses in 5q13,3, 21q22,11, and 10q21.3. 7 They concluded that DIA and DIG "represent a histological spectrum of the same tumor rather than two separate entities." 7 DIA/DIG is characterized by frequent, but not invariable, dural attachment and a reticulin-rich, spindle cell stroma containing connective tissue due to the prominent leptomeningeal involvement. 1 The potential for histological misdiagnosis exists due to the fact that these tumors contain varying proportions of neoplastic glial, neuronal, and poorly differentiated cells, the latter lending a "small blue cell tumor" feature to the tumor. The primitive-appearing element can lead to misdiagnosis of a WHO grade IV embryonal tumor. DIA contains only the primitive element plus astrocytic tumor cells, while in DIG, the astrocytic tumor population predominates but, in addition, a neoplastic ganglion cell component is identified. The latter is usually composed of larger sized ganglion cells.
While the presence of ganglion cells in DIG could suggest some biological overlap with conventional ganglioglioma, the latter lacks the very young patient age, massive size, and rich desmoplastic investiture of DIG. Gangliogliomas in pediatric patients are known to harbor v-Raf murine sarcoma viral oncogene homolog B (BRAF) V600E mutations, variably reported as 35%, 8 50%, 9 and >60% 10 of cases. This has prompted several previous studies looking for BRAF mutations in DIAs and DIGs. 7, [11] [12] [13] By varying methodologies, BRAF V600E mutation was found in one of two cases (listed as DIG), 13 one of 14 cases (listed as DIA), 7 and two of 18 cases (listed as one DIA and one DIG). 11 In addition, single cases with BRAF V600E mutation (listed as DIA) 12 We report this case to emphasize that mutational analysis, rather than BRAF VE1 immunohistochemistry (IHC), which only identifies the mutant protein resulting from the far more common V600E mutation, may be required to fully identify BRAF-mutated examples. We also tested retrospectively five additional cases in our files to add to the numbers of tested cases in the literature.
MATERIALS AND METHODS

Patient accrual
All studies were conducted in compliance with local and federal research protection guidelines and institutional review board regulations (COMIRB #95-500 and 05-149). Retrospective review of 
Routine histology and IHC
Tissues were fixed in 10% buffered formalin, paraffin-embedded, and cut at 5 m. All cases were stained with Harris hematoxylin and eosin and Gomori reticulin. IHC was performed on formalin-fixed, 
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BRAF gene mutation sequencing
Direct (Sanger) sequencing was performed as previously described. 9 Library preparation for next-generation sequencing was performed 
RESULTS
Six patients were identified (four males-two females), ranging in age from 1 to 12 months of age (see Table 1 ). There were three DIAs and three DIGs, including one with prominent aggregates of large ganglion cells (Patient 6). All patients were within the classic, very young age range for DIA/DIG.
Magnetic resonance imaging (MRI) features were consistent with
DIA/DIG in all cases, providing pathological-neuroimaging correlation.
There were overlapping MRI features regardless of DIA or DIG status ( Fig. 1) . All tumors were cerebral hemispheric in location, large, cystic, and enhancing. Patients 1 (Fig. 1A) and 6 ( showed unilocular lesions with more obvious superficial, dural-based relationship. Of the six patients, four underwent a complete resection, one had a near-total resection, and the last patient had a subtotal resection; this is detailed in Table 1 .
All tumors contained a connective tissue rich component that predominated in the superficial portions of the tumor and showed numerous interspersed cytologically bland astrocytic tumor cells ( Fig. 2A) .
These areas manifested a reticulin-rich matrix (Fig. 2B) . Tumor cells in all six examples were mostly astrocytic, as proven by IHC for GFAP (Fig. 2C) . DIAs contained little or no ganglion cell component and no 3A and 3B ). In addition, discrete aggregates containing numerous large, closely juxtaposed, tumor ganglion cells were also found (Fig. 3C) . Ganglion tumor cells manifested abundant basophilic cytoplasm, large vesicular nuclei, nucleoli, Nissl substance (Fig. 3C) , and strong cytoplasmic synaptophysin immunoreactivity, which further highlighted their bizarre shapes (Fig. 3D) . Unlike pleomorphic xanthoastrocytoma or ordinary ganglioglioma, no perivascular nonneoplastic lymphocytic cuffing, eosinophilic granular bodies, or Rosenthal fibers were present. As is typical of some DIA/DIG, occasional areas showed extension of tumor along Virchow-Robin spaces. Although the clinical outcome was favorable in all six of our patients and all remained alive 9-195 months post diagnosis (see Table 1 ), other authors have described examples of DIA/DIG with 15 is larger, while the above-cited studies of 14 7 and 18 11 patients drew their cohorts from more than one institution.
Our study not only expands the numbers of DIA/DIGs tested for BRAF mutation, but additionally documents a unique BRAF V600D mutation. We report this case due to our inability to locate any BRAF favorable in all six of our patients (see Table 1 ), other authors have described examples of DIA/DIG with progressive disease 2 that could potentially respond to targeted therapy if a BRAF mutation is demonstrated.
Interestingly, while we were unable to identify BRAF V600D mutations in gliomas of any type, including DIA/DIG in standard databases, this mutation is not unheard of in systemic malignancies. For example, in systemic melanomas, while the majority of cases with BRAF mutations manifest the common BRAF V600E (seen in 90%), BRAF V600K mutation is found in 5-6% and BRAF V600D is identified infrequently; some data suggest that melanomas with these rare mutations types might respond to BRAF inhibitors. 16 Thus, identifying any type of BRAF mutation in a DIA/DIG opens the possibility of use of targeted therapies, if needed for subtotally resected cases with recurrence, or even rare leptomeningeal dissemination. 2 
